Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) Director Sells $219,120.00 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Maria C. Freire sold 8,250 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total value of $219,120.00. Following the sale, the director now directly owns 91,007 shares in the company, valued at $2,417,145.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Exelixis Stock Performance

EXEL opened at $26.35 on Monday. The stock has a market cap of $7.99 billion, a price-to-earnings ratio of 41.17, a price-to-earnings-growth ratio of 0.60 and a beta of 0.54. The firm’s fifty day moving average is $23.15 and its 200 day moving average is $22.48. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $27.53.

Hedge Funds Weigh In On Exelixis

Large investors have recently made changes to their positions in the business. Fisher Asset Management LLC grew its position in shares of Exelixis by 232.6% during the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares in the last quarter. GAMMA Investing LLC bought a new position in Exelixis in the 4th quarter worth approximately $27,000. Rise Advisors LLC purchased a new stake in Exelixis during the 1st quarter valued at approximately $28,000. Park Place Capital Corp bought a new stake in shares of Exelixis during the second quarter valued at approximately $45,000. Finally, USA Financial Formulas lifted its holdings in shares of Exelixis by 1,548.0% in the fourth quarter. USA Financial Formulas now owns 2,060 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,935 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EXEL has been the topic of several research analyst reports. TD Cowen upped their target price on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. JMP Securities lifted their target price on shares of Exelixis from $27.00 to $29.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Exelixis in a research note on Friday, May 3rd. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Finally, Stephens began coverage on shares of Exelixis in a research report on Tuesday, May 14th. They set an “equal weight” rating and a $23.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $27.43.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.